Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers develop new treatment to improve recovery after spinal cord injury
"This discovery is an exciting step in uncovering other possible combined treatments that have the potential to improve cell transplant therapy." Dr Jon Prager, RVC.

Teams create novel combined cellular and molecular treatment.

New research conducted by the Royal Veterinary College (RVC) in collaboration with the University of Bristol has led to the development of a new type of combined cell treatment that can help to improve recovery after spinal cord injury in companion animals and, ultimately, humans.

There is currently no cure for paralysis caused by damage to nerves in the spine, however, it is possible to inject cells from the nose – called olfactory ensheathing cells – into these damaged nerves. This has shown to improve walking in both experimental and companion animals and, though it is also known to be safe for humans, it has not been tested in a full clinical trial.

Another potential treatment is the injection of a molecule called chondroitinase. This has also improved recovery in experimental animals and pet dogs.

The research teams aimed to combine these two promising treatments into one, developing dog olfactory ensheathing cells that can create and release chondroitinase.

Injecting this new type of cell transplant into the spinal cord improved recovery of hand movements after spinal cord injury in rats. The treated subjects were shown to have increased accuracy when reaching and grasping compared to control subjects or those receiving cells alone.

Dr Jon Prager, postdoctoral researcher at the RVC, said: “Spinal cord injury causes chronic paralysis and incontinence, and remains a major worldwide healthcare burden, with no regenerative treatment clinically available. This study suggests that our genetically engineered cellular and molecular approach is a feasible combination therapy for spinal cord injury.

“Our findings show that this treatment leads to a modest improvement in rats’ ability to pick up treats and we are incredibly excited to see how the next stage of the research goes. This discovery is an exciting step in uncovering other possible combined treatments that have the potential to improve cell transplant therapy.”

Moving forward the researchers aims to test the efficacy of these treatments in ‘real-life’ injuries, such as those sustained by companion dogs and people.

The full paper is available to view here.

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.